The Metro: Are GLP-1s outweighing the body positivity movement?

In the 2010s, the effort to uplift people with bigger bodies shifted online. The Body Positivity Movement expanded its reach with the advent of social media and trendy hashtags. However, that momentum appears to be slowing with the growing popularity of weight loss medications. 

GLP-1 agonists are FDA approved weight loss medications that were approved in 2014 to treat patients who suffer from obesity. Nowadays, the drug is in high demand. The percentage of U.S. adults who use it doubled from 2024 to 2025. At the same time, obesity rates in the U.S have been declining since 2022.  Could this be the end of the body positivity movement of this era? What does embracing weight loss drugs say about the shifting standards of beauty in the U.S?

Randy Seeley is the director of the Michigan Nutrition Obesity Research Center at the University of Michigan. He is also a paid consultant to pharmaceutical companies Lilly and Novo which manufacture drugs like Zepbound, Mounjaro and Ozempic. He joined the program to explain how GLP-1s are being used for both health and vanity.

Then Kendrin Sonneville, an associate professor and Chair of Nutritional Sciences at the University of Michigan joined to talk about how GLP-1 medications are changing the way we view bigger bodies.